Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Dutta

Showing results (21-30 of 114) with videos related to

Pageof 12
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|July 23, 2022
Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation modelMario Nagase, Sameer Doshi, Sandeep Dutta, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 20, 2023
A multistate platform model for time-to-event endpoints in oncology clinical trialsChih-Wei Lin, Mario Nagase, Sameer Doshi, et al.
Biopharmaceutics & Drug Disposition|September 21, 2004
Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteersSandeep Dutta, Yiming Zhang, Lillian L Lee, et al.
Clinical Pharmacology and Therapeutics|January 29, 2024
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic ModelAnnie Lumen, Xinwen Zhang, Sandeep Dutta, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 20, 2021
Pharmacokinetics, Disposition, and Biotransformation of [<sup>14</sup>C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral DoseAshit Trivedi, Jan Wahlstrom, Mia Mackowski, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2021
The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancerMichael Z Liao, Hans Prenen, Sandeep Dutta, et al.
Journal of Clinical Pharmacology|May 14, 2011
Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trialsAhmed A Othman, Wolfram Nothaft, Walid M Awni, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 23, 2026
Integration of Time-Varying Pharmacometric Modeling With Cox Regression for Time-to-Event Analysis in NONMEMChih-Wei Lin, Po-Wei Chen, Sameer Doshi, et al.
British Journal of Clinical Pharmacology|September 13, 2012
Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trialsAhmed A Othman, Wolfram Nothaft, Walid M Awni, et al.
Journal of Cardiovascular Pharmacology|January 5, 2022
Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection FractionPo-Wei Chen, Ashit Trivedi, Edward Lee, et al.
Pageof 12

Showing results (21-30 of 114) with videos related to

Sort By:
Pageof 12
Journal of Pharmacokinetics and Pharmacodynamics|July 23, 2022
Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation modelMario Nagase, Sameer Doshi, Sandeep Dutta, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 20, 2023
A multistate platform model for time-to-event endpoints in oncology clinical trialsChih-Wei Lin, Mario Nagase, Sameer Doshi, et al.
Biopharmaceutics & Drug Disposition|September 21, 2004
Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteersSandeep Dutta, Yiming Zhang, Lillian L Lee, et al.
Clinical Pharmacology and Therapeutics|January 29, 2024
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic ModelAnnie Lumen, Xinwen Zhang, Sandeep Dutta, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 20, 2021
Pharmacokinetics, Disposition, and Biotransformation of [<sup>14</sup>C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral DoseAshit Trivedi, Jan Wahlstrom, Mia Mackowski, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2021
The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancerMichael Z Liao, Hans Prenen, Sandeep Dutta, et al.
Journal of Clinical Pharmacology|May 14, 2011
Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trialsAhmed A Othman, Wolfram Nothaft, Walid M Awni, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 23, 2026
Integration of Time-Varying Pharmacometric Modeling With Cox Regression for Time-to-Event Analysis in NONMEMChih-Wei Lin, Po-Wei Chen, Sameer Doshi, et al.
British Journal of Clinical Pharmacology|September 13, 2012
Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trialsAhmed A Othman, Wolfram Nothaft, Walid M Awni, et al.
Journal of Cardiovascular Pharmacology|January 5, 2022
Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection FractionPo-Wei Chen, Ashit Trivedi, Edward Lee, et al.
Pageof 12